In vitro characterization of CD133\textsuperscript{lo} cancer stem cells in Retinoblastoma Y79 cell line

Rohini M. Nair\textsuperscript{1}, Murali MS. Balla\textsuperscript{2,3}, Imran Khan\textsuperscript{4,5}, Ravi Kiran Reddy Kalathur\textsuperscript{4,6}, Paturu Kondaiah\textsuperscript{4} and Geeta K. Vemuganti\textsuperscript{1,*}

Abstract

**Background:** Retinoblastoma (Rb), the most common childhood intraocular malignant tumor, is reported to have cancer stem cells (CSCs) similar to other tumors. Our previous investigation in primary tumors identified the small sized cells with low CD133 (Prominin-1) and high CD44 (Hyaluronic acid receptor) expression to be putative Rb CSCs using flow cytometry (FSC\textsuperscript{lo}/SSC\textsuperscript{lo}/CD133\textsuperscript{lo}/CD44\textsuperscript{hi}). With this preliminary data, we have now utilized a comprehensive approach of in vitro characterization of Y79 Rb cell line following CSC enrichment using CD133 surface marker and subsequent validation to confirm the functional properties of CSCs.

**Methods:** The cultured Rb Y79 cells were evaluated for surface markers by flow cytometry and CD133 sorted cells (CD133\textsuperscript{lo}/CD133\textsuperscript{hi}) were compared for CSC characteristics by size/percentage, cell cycle assay, colony formation assay, differentiation, Matrigel transwell invasion assay, cytotoxicity assay, gene expression using microarray and validation by semi-quantitative PCR.

**Results:** Rb Y79 cell line shared the profile (CD133, CD90, CXCR4 and ABCB1) of primary tumors except for CD44 expression. The CD133\textsuperscript{lo} cells (16.1 ± 0.2%) were FSC\textsuperscript{lo}/SSC\textsuperscript{lo}, predominantly within the G0/G1 phase, formed larger and higher number of colonies with ability to differentiate to CD133\textsuperscript{hi} cells, exhibited increased invasive potential in a matrigel transwell assay (p < 0.05) and were resistant to Carboplatin treatment (p < 0.001) as compared to CD133\textsuperscript{hi} cells. The CD133\textsuperscript{lo} cells showed higher expression of several embryonic stem cell genes (HOXB2, HOXA9, SALL1, NANOG, OCT4, LEFTY), stem cells/progenitor genes (MSI2, BMI1, PROX1, ABCB1, ABCB5, ABCG2), and metastasis related gene-MACC1, when compared to the CD133\textsuperscript{hi} cells.

**Conclusions:** This study validates the observation from our earlier primary tumor study that CSC properties in Rb Y79 cell line are endowed within the CD133\textsuperscript{lo} population, evident by their characteristics- i.e. small sized, dormant in nature, increased colony forming ability, differentiation to CD133\textsuperscript{hi} cells, higher invasiveness potential, drug resistance and primitive gene expression pattern. These findings provide a proof of concept for methodological characterization of the retinoblastoma CSCs with future implications for improved diagnostic and treatment strategies.

**Keywords:** Retinoblastoma, Stem-like cancer cells, Cancer stem cell markers, CD133 (Prominin), Flow cytometry

* Correspondence: glkvemuganti@gmail.com
\textsuperscript{1}School of Medical Sciences, University of Hyderabad, Hyderabad 500046, India
\textsuperscript{2}Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
landscapes (e.g. high MYCN expression) that facilitate aggressive tumor formation similar to that seen in RB1(−/−) tumors [4, 6]. The hypothesis of cancer stem cells (CSCs), which is now synonymous with tumor initiating cells (TICs) and stem-like cancer cells (SLCCs), originated first from blood related cancers, wherein a small fraction of the tumor cells were reported to be responsible for tumor formation and were attributed with properties of normal stem cells such as quiescence, proliferation, and drug resistance [7]. The salient features of both CSCs and normal stem cells are their potency for self-renewal and forming a cellular hierarchy within the tumor/normal tissue. Additionally, both stem cells and CSCs have the ability to differentiate and migrate [8]. In paediatric brain cancers, tumor derived progenitors form neurospheres that can be passed at clonal density and are able to self-renew. These cells express several genes characteristic of neural and other stem cells including CD133, NESTIN, SOX2, MSII, BMI1, MELK, OCT4, etc. [9, 10].

In retinoblastoma, several studies have reported the presence of stem cells in both primary tumors as well as cell lines, using a few properties attributed to cancer stem cell phenotype, ability to actively extrude drugs, slow cycling, clone formation post nutrient starvation, etc. [11–16]. Seigel and co-workers provided evidence of putative stem-like cells in primary Rb tumor cells using a bi-parameter model by flow cytometry with a phenotype of low CD133, high CD44 expression and small sized cells (FSClo/SSClo/CD133lo/CD44hi) expressing progenitor cell markers (PROXI and SYX1A) [18]. Similar to our study on primary Rb, we observed the two parametric distribution of Rb Y79 cell line with a small subset of cells exhibiting low forward and side scatter profile with low CD133 expression (FSClo/SSClo/CD133lo). It is interesting to note that other than the studies on normal developing retina and Rb deficient retinal cells, which suggests that CD133 expression is low in progenitors and high in differentiated photoreceptors [19, 20], the Rb tumor studies suggest that CD133 expression is specific to cancer stem cells [15, 17, 21]. This prompted us to investigate the surface marker profile of Y79 cell line and compare the functional properties of CSCs [22] within the CD133 sorted populations.

Methods
Cell culture
Retinoblastoma Y79 cells (Riken: RCB1645 Y79 - a generous gift from Dr. S. Krishnakumar, Sankara Nethralaya, Chennai, India) were revived and cultured in Roswell Park Memorial Institute-1640 (RPMI-1640) media supplemented with 10% Fetal Bovine Serum (FBS), antibiotics and L-Glutamine (Gibco™, ThermoFisher Scientific). The cell line was authenticated at the time of purchase from Riken. Regular mycoplasma tests have been carried out and the experiments were conducted in compliance with good laboratory practices (GLP). Media was changed every 3 days and the cells were sub-cultured following observation of cell confluency of about 70%. Enrichment and characterization of putative cancer stem cells were carried out in the cultured Y79 cells and then sorted using the surface marker, CD133. In vitro functional characterization of the sorted subsets was carried out to assess the cell cycle status, clone forming ability, differentiation, invasion, chemoresistance and gene expression signature.

Flow Cytometry analysis and sorting
One million Y79 cells were stained with directly labelled primary antibodies (CD133-Miltenyi Biotech, CD44, CD90, CXCR4-Ebioscience and ABCB1-Abcam) for 45 min at 4 °C. The antibodies were standardized by varying their dilutions and checking the expression percentage. The cells were then washed thrice with wash buffer to remove excess antibody and run in the BD LSRFortessa™ flow cytometry analyser and the BD FACSDiva™ software version 6.2. Appropriate controls were used for the experiments. A total of 20,000 to 50,000 events were acquired for analysis. The cells were gated based on size, granularity and doublet discrimination as described previously [18]. In brief, Y79 cells were first selected based on forward and side scatter, and the doublets were excluded using the doublet discrimination plots. The negative control (unstained cells) is used to set the laser voltages, sorting gates and establish the Allophycocyanin (APC) expression profile for the population. The labeled cells were then run through the cytometer and the two populations (CD133hi and lo) are collected in tubes with medium containing 2X antibiotic solution. The post-sort purity and viability was determined. The sorted cells were then used for CSC characterization.

Magnetic activated cell sorting
The Y79 cells in their growth phase were sorted using the CD133 Microbead Kit according to the manufacturer’s protocol (Miltenyi Biotec Inc., Auburn, CA). Briefly, the cells were centrifuged at 300 g for 10 min and resuspended in 300 μL of buffer per 10⁷ cells. 100 μL
of FcR Blocking Reagent was added and mixed well. To the cell suspension, 100 μL of CD133 Microbeads were added, mixed well and incubated for 30 min at 4 °C. The cells were washed twice with the buffer and resuspended in 500 μL of buffer. Magnetic separation was carried out in LS columns using the MiniMACS™ separator and the two populations were collected in labelled tubes. The sorted cells were then assessed for CD133 expression using flow cytometry for determining the sorting purity and further experiments were carried out following viability count using Trypan blue.

**Cell cycle analysis**
Sorted CD133\(^{hi}\), CD133\(^{lo}\) and unsorted total Y79 cell populations were pelleted by centrifugation and resuspended in PBS with 50 μg/ml propidium iodide for cell cycle analysis. After incubation on ice for 30 min, cell populations were treated with 0.25 mg/ml RNaseA for 45 min at 37 °C to remove RNA. Cells were analysed by flow cytometry at an excitation wavelength of 488 nm and the cell cycle histogram was assessed using the BD FACSDiva software.

**Soft agar Colony formation assay and differentiation**
The sorted CD133\(^{hi}\) and CD133\(^{lo}\) Y79 cells were grown in agarose as single cells to assess their colony forming potential. Briefly, a base coat of 0.8% agarose was added into the wells of a 24-well plate and further covered with cell suspension (1000 cells/well in 0.48% agarose). Plates were incubated for 2 weeks following which the resulting colonies were then fixed with 3.7% paraformaldehyde and stained with crystal violet. The images of the colonies were taken at 1.5X and 4X magnification and analysed using ImageJ and OpenCFU software. For colony forming efficiency (CFE) analysis, colonies greater than 50 cells were counted and percentage of colonies were calculated. The morphology of the colonies was assessed for characteristics of holoclones, meroclonies and paraclonies. The CD133\(^{lo}\) clones were then expanded and the expression of CD133 was checked for four passages in vitro.

**Matrigel Transwell invasion assay**
The Matrigel transwell invasion assays were performed using Corning transwell 24-well inserts with 8 μm pore size as per manufacturer’s instructions. Briefly, \(10^4\) cells each of CD133\(^{hi}\) and CD133\(^{lo}\) subsets were serum-starved overnight and plated into 100 μl serum-free medium onto the inner chamber of the transwell plate, which was previously coated with Matrigel (1:50) (BD Biosciences). The bottom well was then filled with 600 μl of media with 10% serum. The cells were incubated for 24 h at 37 °C and 5% CO\(_2\) level. Following incubation, the media was removed from the plate and the non-invasive cells were scraped off from the upper side of the insert and the cells in the lower side of the membrane were fixed in 3.7% Paraformaldehyde (PFA), washed, and stained using crystal violet. Experiments were performed in triplicate transwell and the invaded cells were quantified by counting the average number of cells per 20X field of view and 10 fields per chamber.

**Cytotoxicity assay**
The sorted Y79 cells (CD133\(^{hi}\) and CD133\(^{lo}\)) were assessed for chemoresistance against Carboplatin (Alkem Pharmaceuticals) using MTT assay. Briefly, 5000 cells/90 μL media each of the populations were seeded in a 96 well plate and incubated overnight at 37 °C and 5% CO\(_2\) level. Carboplatin was added at varying concentrations (1 μM–100 μM) at a final volume of 10 μL in the wells and incubated for 48 h. Following incubation, 20 μL of 5 mg/mL MTT reagent was added to each well and incubated for 3 h. The Formazan crystals formed were dissolved in 100 μL of Dimethyl sulfoxide (DMSO) and the absorbance was recorded at 595 nm using an ELISA plate reader. The percentage of viability was calculated compared to the controls for each of the population and drug concentration.

**Gene expression microarray and pathway analysis**
Microarray was performed in duplicates using human whole genome (4x44K) cDNA arrays (Agilent technologies, USA). Labelling reactions were performed using 500 ng of RNA from CD133\(^{hi}\) and CD133\(^{lo}\) populations. Labelling of the probes was carried out using the Low RNA input linear amplification kit (Agilent technologies, USA) where total RNA was first converted to cDNA using T7-oligo d(T) primers. From this cDNA, labelled cRNA was generated via an in vitro transcription reaction using T7 RNA polymerase and Cy3 (for CD133 \(^{hi}\) population) or Cy5 (CD133 \(^{lo}\) population) labelled CTP respectively. Probes with higher labelling efficiency (specific activity ≥8 pmol Cy3 or Cy5/ng cRNA) were selected for competitive hybridization as per the manufacturer’s instructions. 825 ng each of Cy5 and Cy3 labelled cRNAs from CD133\(^{hi}\) and CD133\(^{lo}\) populations were mixed and added to hybridization buffer and placed on the array. Hybridization was done in a chamber (Agilent technologies, USA) for 17 h at 65 °C with gentle rotation. The slide was scanned and image was analysed using feature extraction tool version 9.5.3.1 (Agilent technologies, USA) and data was analysed using GeneSpring version 10 (Agilent technologies, USA). Lowess algorithm was used to normalize the data. Fold change was calculated based on ratio of Cy5/Cy3 intensities and genes with fold change ≥ + 1.5 or ≤−1.5 where considered differentially regulated for which p-values were assessed. Further, we performed functional enrichment analysis to identify enriched biological processes and pathways in our differentially regulated genes using DAVID bioinformatics resources (version
6.8) and KEGG pathway database [23, 24]. Biological processes and pathways with \( p \)-value \( \leq 0.05 \) where considered significantly enriched. Additionally, we validated the up-regulated genes involved in pathways using Polymerase Chain Reaction (PCR).

**Semi quantitative PCR**

Total RNA was isolated from the sorted populations by the TRizol™ method of solubilisation and extraction. The isolated RNA was quantified using Nanodrop and cDNA was prepared using SuperScript™ First-Strand Synthesis System kit (Invitrogen). The prepared cDNA was then analysed for the expression of \( ACTB \), \( BMI1 \), \( CD133 \), \( NANOG \), \( PROX1 \), \( MACC1 \), \( SNAI2 \) and \( ABCG2 \) genes by semi-quantitative PCR. The primer sequences used for PCR are enlisted in Table 1. The samples were then observed for gene expression using a 2% agarose gel and the image was captured using BioRAD ChemiDoc™ and Image Lab software.

**Statistical analysis**

The quantitative data were stated as Mean ± SEM, and GraphPad Prism (GraphPad Software, La Jolla, CA) was used for unpaired Student’s t-test and ANOVA with Bonferroni’s Post-hoc tests. The representative images were analysed using ImageJ software. The experiments were repeated at least thrice with biological replicates and \( p < 0.05 \) was considered for statistical significant difference between the groups.

**Results**

**Phenotypic characterization of Y79 cells and CD133 cell sorting**

Surface marker analysis was carried out in Y79 cell line to analyse the putative CSC markers similar to those observed in primary Rb tissues. The flow cytometry analysis showed the expression of the surface markers on Y79 as depicted in Fig. 1. CD133, CD90, CXCR4, CD44 and ABCB1 constitute 83.25 ± 0.85, 79.7 ± 1.3%, 14.4 ± 0.5%, 0.1 ± 0.1%, and 4.34 ± 0.8% respectively (Fig. 1a-i). The sorting purity of CD133lo and CD133hi was obtained as ≥90% (Fig. 1j, k). Cell viability for the populations was found to be 86.88 ± 3.89% and 87 ± 2.79% respectively.

**CD133lo cells are predominantly in the resting phase of cell cycle**

The cell cycle status was assessed in the two populations using flow cytometry to compare the dormant and proliferative compartments. Cell cycle analysis revealed that the majority of the CD133hi population segregated with resting phase i.e. G0/G1 (83.3 ± 4.1%). On the contrary, 81.1 ± 4.1% of CD133hi cells were in S/G2/M phase as shown in Fig. 1l-n, suggesting that CD133hi cells are mitotically active when compared to dormant CD133lo cells.

**CD133lo cells are clonal in nature and differentiate to CD133hi cells in vitro**

In order to assess the clonal nature and differentiation ability of the CSCs, soft agar clonal assays and further expansion was carried out. In the soft agar assays, after 2 weeks of culture, CD133lo cells formed larger number of colonies (<50 cells) when compared to CD133hi cells (107.3 ± 7.4 vs 53.25 ± 3.9, \( p = 0.0007 \)) (Fig. 2a). Colonies formed by CD133lo cells were larger in area when compared to the CD133hi subset (226.0 ± 31.2 vs 98.06 ± 1.862, \( p = 0.0064 \)) (Fig. 2b). The colonies of CD133lo cells were compact clusters of uniformly small cells while the CD133hi cell colonies were irregular, with loosely packed large cells (Fig. 2c). Serial passaging of the CD133lo colonies revealed increased level of CD133 expression by passage 4 and 5 (34.5 ± 0.1 to 38.8 ± 1.3%), as shown in Fig. 2d.

**CD133lo cells exhibit increased chemoresistance to Carboplatin treatment**

MTT assay was carried out to assess cytotoxicity of Carboplatin on CD133 sorted Y79 cells following 48 h exposure. CD133lo cells were observed to be more resistant to Carboplatin treatment when compared to CD133hi cells following 48 h exposure (\( p < 0.001 \)) indicating the phenomenon of chemoresistance in this population (Fig. 3b).

**Table 1**

| S No. | Gene       | Forward primer | Reverse primer |
|-------|------------|----------------|----------------|
| 1.    | ACTB       | atgcagaaggagatcactgc | tcatagtccgcctagaagca |
| 2.    | CD133      | cccctctgggtggatcttcct | agggctgcgttcgatcttc |
| 3.    | BMI1       | ggctcaagatggcccgccctg | ttctggtggtcagatgctttc |
| 4.    | OCT4       | ccacacagccccagacgatcct | ttcaaagagagcctcaag |
| 5.    | PROX1      | caagtgggagcagcttgggt | gcagactgcagagagggag |
| 6.    | MACC1      | ccggctcgagagagcgccag | ttcagagagcttcagag |
| 7.    | SNAI2      | tggcagagagagatgagcgcc | tgaggccctcgagtcgtct |
| 8.    | ABCG2      | cggactcagttatcgttgga | cgagctgtaatgagag |

Nair et al. BMC Cancer (2017) 17:779
Gene expression microarray and pathway analysis of CD133<sub>lo</sub> vs CD133<sub>hi</sub> cells

Comparative gene expression analysis was carried out in the two populations of Y79 cell line to analyse the differentially regulated genes. The top 30 up-regulated and down-regulated genes with fold change ≥ +1.5 or ≤ −1.5 are listed in Tables 2 and 3. The gene expression analysis of CD133<sub>lo</sub> cells, in comparison to CD133<sub>hi</sub> cells, had an up-regulation of 2945 genes (≥1.5 fold) and down-regulation of 4531 genes (≤1.5 fold). The heat map generated for the deregulated genes along with the hierarchical clustering of CD133<sub>lo</sub> and hi populations are represented in Fig. 3d. Through functional enrichment analysis, we identified Purine metabolism pathway (p = 0.009), TGF-β signalling pathway (p = 0.009), p53 signalling pathway (p = 0.017), Jak-Stat signalling pathway (p = 0.047), cytokine-cytokine receptor interaction pathway (p = 0.034), and oxidative phosphorylation pathway (p = 0.012) to be significantly over-expressed in the CD133<sub>lo</sub> subset. The embryonic and neural stem cell genes up-
regulated (fold change <1.5) in CD133lo population were HOXB2, HOXA9, SALL1, LEFTY, ABCB1, ABCB5, MUSHASHI2, BMI1 (Table 4). Comparative analysis of several stem cell, progenitor, invasion and chemoresistance related genes was further carried out using Reverse transcriptase PCR. BMI1, OCT4, NANOG, PROX1, MACC1, and ABCG2 were observed to be up-regulated in the CD133lo cells when compared to CD133hi cells (Fig. 3c).

**Discussion**

Retinoblastoma is a small round cell tumor that comprises of rapidly dividing tumor cells, arising from the retina, within extensive areas of ischemic necrosis as they outgrow their own blood supply [25]. This study attempts to characterize the stem-like cancer cells in the well-established Rb Y79 cell line using the surface marker widely used in other tumors for CSC isolation—CD133 (Prominin). The study confirms that Y79 Rb cell line harbours stem-like cancer cells endowed within the CD133lo enriched population. This was demonstrated by CSC properties such as exclusive surface marker phenotype, size and percentage, slow cycling/dormancy, clone forming ability and differentiation, invasiveness, chemoresistance and primitive gene expression markers.

While in several solid tumors [26], CD133hi cells are heralded as the cells with CSC properties, there are also contrasting reports of CD133lo subset being capable of exhibiting tumorigenicity and clone forming ability in tumors such as Glioma [27], Glioblastoma [28], Colon cancer [29], etc. Sun and co-workers reported that in neural stem cells, the CD133 negative population are clonogenic and slow cycling in nature [30]. In the developing retina, CD133, which is a conserved surface glycoprotein, is reported to be acquired upon differentiation. In support of this observation is the study by Lakowski et al. who reported that the neuroblastic layer of developing photoreceptors showed lower expression of CD133 when compared to the outer segments of the photoreceptors that had intense expression [19]. Also, Xu and their group showed that in Rb deficient retinal cells, CD133 expression was strong in maturing photoreceptors and weak in the retinal progenitor cell population [20]. Studies have shown that CD133 (Prominin) is crucial for photoreceptor outer segment morphogenesis and the mutations within the gene is associated with several retinal dystrophies which ascertains its pivotal role in the visual cycle [31]. It therefore appears logical to speculate that the CD133 is a marker acquired after...
cellular differentiation in Retinoblastoma, and the putative CSCs would lack the expression similar to progenitors, since they are believed to arise from the undifferentiated retinal cells.

One of the challenging issues in characterizing CSCs is the sorting/enrichment strategies which are crucial for validating the functional attributes of stem-like cancer cells [22]. With regard to Rb primary tumors, our earlier work highlighted, using a bimodal pattern, that FSClo/SSClo CD133lo/CD44hi cells show more primitive markers as compared to CD133hi cells [18]. In contrast to our observation of CD133lo cells as the Rb CSC subset, Hu et al. using the principle of generating stem-like cancer cells by serum-free culture in WERI-Rb cell line, documented higher percentage of CD133 hi cells within the clones when compared to cultured WERI-Rb cells [15]. Based on the evidence of varying expression of CD133 expression in different stages of embryonic stem cell development and its differentiation into neural lineage [32], it is logical to speculate that there could be a range of expression within tumors of different lineages. Similarly, it could also be affected by modifications induced in primary tumors and the culture conditions of cell lines, which needs to be explored further. This interesting and contrasting expression possibly reflects the evolving concept that the CSC properties of tumor cells enhance or decrease in a gradual fashion and is possibly tissue specific. The surface markers CD90 and CXCR4 are within the range reported by our earlier study in patient samples and correspond to 79.7 ± 1.3% and 14.4 ± 0.5% respectively. This study confirms the presence of CSCs in Y79 cell line comparable to the surface markers observed in the primary tumors [18], however with one major difference which is the absence of CD44 expression in all cells. Lack of expression of CD44 (Hyaluronic acid receptor) could possibly be attributed to culture conditions and absence of hyaluronic acid, which is abundantly present in the vitreous fluid [33]. This observation is also supported by Ma et al., who showed that long-term serum-free cultures of

Fig. 3 CD133lo cells exhibited invasive ability, resistance to Carboplatin treatment and CSC based gene expression signature. a) Graphical representation of the Matrigel Transwell Invasion assay showing the average number of invaded cells in both populations in response to a chemoattractant (p < 0.05). b) CD133lo cells were observed to be more resistant to Carboplatin treatment when compared to CD133hi cells following 48 h exposure (p < 0.05). c) Gene signature of CD133lo cells compared to CD133hi cells with differential expression of stem cell, progenitor, invasion and chemoresistance related genes (p < 0.05). d) Heat map generated for the genes in CD133hi population deregulated by 2-fold change compared to CD133lo cells and hierarchical clustering of CD133lo and hi populations.
neurospheres from primary Retinoblastoma showed increased expression of CD44 marker in addition to CD133 when compared to the in vitro differentiated cells [21]. The evidence from retinal studies and increasing expression of CD133 in long-term cultures of Rb supports our observation of CD133 as a marker of differentiation. A thorough comparison of CSC functional properties between the CD133 enriched populations, that was lacking in earlier reports, is highlighted in this study which ascertains the robustness of CD133 phenotype as a CSC marker.

Another important characteristic of CSCs appears to be the dormancy of cells and segregation within the G0/G1 phase of the cell cycle indicating that they are inherently slow cycling. It has been reported that CSCs are quiescent/slow cycling in nature unless triggered by selection pressure [34]. While the bulk of the tumor population remains in a constant balance between the G1/G2/M phases, CSCs are believed to remain in a G0/G1 phase [35]. This attribute makes the CSCs resistant to conventional therapies that target the rapidly dividing tumor cells. In ovarian cancer, Kusumbe et al. showed that the quiescent fraction of the tumor exhibited stem cell activity and ability to revert to a state of self-renewal and differentiation [36]. Our study also demonstrated that CD133lo cells were observed to be in the G0/G1 phase of the cell cycle.
phase implicating that these are the slow cycling and dormant cells.

The ability to form large colonies within a short period is another hallmark of stem-like cancer cells. Using the soft agar colony forming assay, the study documented that the CD133lo cells were capable of forming larger colonies in soft agar when compared to smaller colonies of the CD133hi subset in 2 weeks of culture. Siegel et al. has shown the evidence for neurosphere forming ability of Y79 cells in culture for 5 days [13]. However, clone forming ability of CD133 sorted populations is one of the novel features of this study. The experiments revealed CD133lo cells formed increased number of large sized colonies as against CD133hi cells in an anchorage independent colony formation assay. This is in concordance with the defined characteristics of holoclones and paraclones in human epidermal keratinocytes by Barrandon and Green and the more recent study on prostate cancer cell clones by Beaver et al. [37, 38]. The CD133lo cells form large clusters of small sized cells with a smooth outline representative of holoclones, whereas CD133hi cells form much smaller colonies with irregular margins depicting paraclones. CD133lo colonies exhibited larger colony area than the CD133hi clusters after 2 weeks hinting at their ability to self-renew and proliferate. The CD133lo population with higher clonogenicity

| Gene ID   | Gene Name                                      | PValueLogRatio  |
|-----------|------------------------------------------------|-----------------|
| A_24_P938577 | follicular lymphoma variant translocation 1 | 2.31E-04        |
| A_24_P911519 | unknown                                      | 4.63E-05        |
| C1orf12   | coiled-coil glutamate rich protein 1 [Homo sapiens (human)] | 3.55E-14 |
| A_24_P942870 | unknown                                      | 1.29E-02        |
| TSHR      | thyroid stimulating hormone receptor [Homo sapiens (human)] | 4.27E-02 |
| A_24_P800363 | AU146536 HEMBB1 Homo sapiens cDNA clone HEMBB1000770 | 2.28E-01 |
| CDH6      | cadherin 6 [Homo sapiens (human)]           | 5.85E-02        |
| A_24_P376029 | A_24_P376029                                | 1.00E + 00      |
| GFM1      | G elongation factor mitochondrial 1 [Homo sapiens (human)] | 6.18E-02 |
| A_24_P64246 | a_24_P376029                                | 5.80E-02        |
| A_32_P849727 | A_24_P64246                                 | 1.00E + 00      |
| DLX2      | distal-less homeobox 2 [Homo sapiens (human)] | 2.77E-16 |
| A_24_P931377 | A_32_P849727                                | 1.56E-18        |
| ROR1      | receptor tyrosine kinase like orphan receptor 1 [Homo sapiens (human)] | 1.17E-06 |
| TFEC      | transcription factor EC [Homo sapiens (human)] | 3.05E-02 |
| MITF      | melanogenesis associated transcription factor [Homo sapiens (human)] | 4.87E-02 |
| ENST00000328752 |                     | 2.47E-06        |
| A_24_P923789 | A_24_P923789                                | 2.10E-02        |
| KNG1      | kininogen 1 [Homo sapiens (human)]          | 1.33E-04        |
| SCN9A     | sodium voltage-gated channel alpha subunit 9 [Homo sapiens (human)] | 1.00E + 00 |
| ENST00000436580 |                  | 1.00E + 00      |
| LMOD3     | leiomodin 3 [Homo sapiens (human)]         | 1.00E + 00      |
| A_24_P923439 | A_24_P923439                                | 9.65E-11        |
| ENST00000481704 |                   | 4.02E-06        |
| FGF5      | fibroblast growth factor 5 [Homo sapiens (human)] | 3.19E-01 |
| A_32_P53093 | A_24_P923439                                | 3.03E-01        |
| CCDC68    | coiled-coil domain containing 68 [Homo sapiens (human)] | 2.63E-20 |
| ENST00000354854 |                | 2.72E-06        |
| CXorf57   | chromosome X open reading frame 57 [Homo sapiens (human)] | 6.69E-03 |
| AK000119  |                                              | 9.79E-04        |
further supports the CSC nature of these cells. The clones could be expanded to passage 5 and showed gradual increase in CD133\textsuperscript{hi} cells with increasing passages suggesting that these cells are capable of self-renewal as well as differentiation to CD133\textsuperscript{lo} cells. In support of this observation is a study by Wang et al. whose group reported that glioma cells that were CD133 negative were capable of forming tumors in nude rats and differentiating into CD133 positive cells [27]. The CSCs generated CD133\textsuperscript{hi} cells upon multiple passages thereby confirming both self-renewal and differentiation. The results from these functional studies of CD133\textsuperscript{lo} vs CD133\textsuperscript{hi} Y79 cells strongly hint that CD133 is a marker of differentiated/mature Rb tumor cells. Validation of this by in vivo tumorigenicity assays would be a valuable study in future.

The invasive potential of these CSCs were evaluated using a matrigel transwell system and the serum starved CD133\textsuperscript{lo} cells exhibited higher invasiveness ($p < 0.05$) when compared to their counterparts. These observations are in agreement with other tumors such as breast cancer, colon cancer, ovarian cancer, etc., in which the CSCs were shown to have increased metastatic potential which concurs with our findings [39–41].

The CD133\textsuperscript{lo} cells also exhibited chemoresistance towards Carboplatin at higher doses ($p < 0.001$), which caused cytotoxicity in the CD133\textsuperscript{hi} population at the end of 48 h exposure. CSCs have shown to have increased chemoresistance which helps them to overcome the therapeutic killing by being able to efflux drugs and resist cell death [42, 43]. In the CD133\textsuperscript{lo} population, it was noted that these cells were not only capable of resisting cell death but also exhibited high proliferation in presence of Carboplatin at the end of a 48 h exposure. On the contrary, CD133\textsuperscript{hi} cells showed a profile similar to the total Y79 population with decreasing viability upon exposure to increasing drug concentrations. It is possible to extrapolate that this could be one of the reasons why in some of the cases of Retinoblastoma, the enucleated eyeballs from patients who have received chemotherapy, showed evidence of viable tumor cells with mitotic activity [44].

Gene expression studies in Y79 cell line revealed several pathways deregulated in the putative CSCs with significant up-regulation of stem cell genes and genes involved in proliferation, chemoresistance and metastasis when compared to the non-CSC population. In support of the evidence in primary tumor cells [18], where CD44\textsuperscript{lo}CD133\textsuperscript{hi} cells exhibited the progenitor cell markers, the CD133\textsuperscript{lo} cells showed similar marker profile except for CD44 expression. Microarray data also shows that there was significant higher expression of embryonic and neural stem cell markers in the stem-like cancer cells of Y79 cell line. Stem and progenitor cell genes such as OCT4, NANOG, BMI1, ABCG2 and PROX1 were highly expressed in CD133\textsuperscript{lo} population. This is in concordance with the gene expression findings by few groups on total and ABCG2 enriched Rb Y79 cells, and WERI-Rb cells [13, 15, 16]. This study also identified an important regulator of metastasis, Metastasis-associated in colon cancer 1 (MACCI) gene to be expressed in Y79 cell line. To the best of our knowledge, this is the first report of MACCI overexpression in Retinoblastoma and specifically within the CD133\textsuperscript{lo} subset of Y79 cell line. This gene has been recently identified as an important factor in tumor cell proliferation, invasion and metastasis in several cancers such as Colon, HCC, Breast, Ovarian, etc. via the c-MET/HGF signalling pathway and is being evaluated as a potential therapeutic target [45, 46].

This study also has its set of limitations, the foremost being lack of a positive co-marker for CSCs. Even though the functional studies validate the CD133\textsuperscript{lo} Y79 cells being endowed with CSC properties, which are in tune with the findings in primary tumors; positive co-markers would add more strength to the data. The multidrug resistance markers that were identified in the microarray study (ABCB1, ABCB5) could be used for co-localization studies in future. Though quiescence is one of the hallmarks of CSCs, documentation of the same is a challenge. Cell cycle

Table 4 Deregulated genes in CD133\textsuperscript{lo} CSCs when compared to CD133\textsuperscript{hi} non-CSCs. Embryonic and Neural stem cell markers up-regulated in CD133\textsuperscript{lo} cells

| Genes highly expressed in CD133\textsuperscript{lo} cells | Gene Name | PValue | LogRatio | Fold change |
|---------------------------------------------------------|-----------|--------|----------|-------------|
| HOXB2                                                   | homeobox B2 | 4.67E-02 | 2.4 |
| HOXA9                                                   | homeobox A9 | 1.77E-06 | 2.3 |
| SALL1                                                   | spalt like transcription factor 1 | 4.35E-07 | 2.2 |
| ABCB1                                                   | ATP binding cassette subfamily B member 1 | 5.60E-04 | 2.2 |
| ABCB5                                                   | ATP binding cassette subfamily B member 5 | 1.24E-01 | 2.1 |
| LEFTY                                                   | left-right determination factor | 7.52E-02 | 2.0 |
| MUSHASHI II                                             | musashi RNA binding protein 2 | 1.97E-01 | 1.6 |
| BMI-1                                                   | BMI1 proto-oncogene, polycomb ring finger | 8.04E-04 | 1.6 |
analysis does not segregate the G0/G1 phases or the different population of cells within the G0 phase of cell cycle, which could also contain differentiated, senescent and stem cells. The study partly addressed it using surface phenotype and clone forming ability, however, segregating the different populations in G0/G1 phase would add value to the study. The CFE measurement was performed for the colonies formed at a 2-week period. Longer incubation period and characterization of the primary clones could further ascertain the clone forming ability and stem cell phenotype. However, the cumulative evidence of all the investigations point towards the CD133lo subset of Rb Y79 cell line which is a novel finding of this study. We believe that similar CSC characterization studies on other Rb cell lines and primary cells would add more strength to the hypothesis.

Conclusions
This study confirms that the CD133lo subset of Rb Y79 cell line is endowed with the characteristics of cancer stem cells as demonstrated by the in vitro functional assays and is in agreement with our previous findings in primary Rb tumors. This insight of tumor heterogeneity and hierarchy is quite vital for designing better strategies towards a successful therapeutic outcome.

Abbreviations
ANOVA: Analysis of variance; APC: Allophycocyanin; BrdU: 5-bromo-2′-deoxyuridine; cDNA: Complementary DNA; CFE: Colony forming efficiency; CMET/Fgf: hepatocyte growth factor receptor/hepatocyte growth factor; CSC: Cancer stem cells; CTR: Cytidine triphosphate; Cy5/Myc: Cyanine 3/5 dye; DAVID: Database for annotation, visualization and integrated discovery; DMSO: Dimethyl sulfoxide; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal Bovine Serum; FSC: Forward scatter; GLP: Good laboratory practices; HCC: Hepatocellular carcinoma; KEGG: Kyoto encyclopedia of genes and genomes; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction; PFA: Paraformaldehyde; Rb: Retinoblastoma; RNA: Ribonucleic acid; Rb: Retinoblastoma; RT: Reverse transcriptase; RPMI: Roswell Park Memorial Institute-1640; SEM: Standard error of the mean; SLCC: Stem-like cancer cells; SSC: Side scatter; SUVG: BLH-T-Ag: simian virus-40 luteinising hormone β sub-unit Large T-antigen; TGF-B: Transforming growth factor beta; TIC: Tumor initiating cells.

GENES
ABCB1: Homo sapiens ATP binding cassette subfamily B member 1; ABCBS: Homo sapiens ATP binding cassette subfamily B member 15; ABCG2: Homo sapiens ATP binding cassette subfamily G member 2; ACTB: Homo sapiens actin beta; ALDH1: Homo sapiens aldehyde dehydrogenase 1 family member A1; BMP1: Homo sapiens BMP1 proto-oncogene, polycomb ring finger; CD133: Homo sapiens prominin 1; CD44: Homo sapiens CD44 molecule; CXCR4: Homo sapiens C-X-C motif chemokine receptor 4; HOXA9: Homo sapiens homeobox A9; HOXB2: Homo sapiens homeobox B2; LEFTY: Homo sapiens left-right determination factor; MACCI: Homo sapiens metastasis associated in colon cancer 1; MELK: Homo sapiens maternal embryonic leucine zipper kinase; MS1: Homo sapiens muscle RNA binding protein 1; MS2: Homo sapiens muscle RNA binding protein 2; MYCN: Homo sapiens proto-oncogene, BH-LH transcription factor; NANO2: Homo sapiens Nanog homeobox; NESTIN: Homo sapiens nestin; OCT4: Homo sapiens POU class 5 homeobox 1; PRX1: Homo sapiens prospero homeobox 1; RB1: Homo sapiens RB transcriptional corepressor 1; SALL1: Homo sapiens spalt like transcription factor 1; SNAI2: Homo sapiens snail family transcriptional repressor 2; SOX2: Homo sapiens SRY (sex determining region Y) box 2; SYX1A: Homo sapiens Syntaxin 1A.

Acknowledgements
The authors acknowledge the central instrumentation facilities of L.V. Prasad Eye Institute and University of Hyderabad, Hyderabad, India.

Funding
This study was supported by academic research grants from the Indian Council of Medical Research (ICMR), Hyderabad Eye Research Foundation (HERF), DST-PURSE (University of Hyderabad) and UPE-II (University of Hyderabad). RMN is supported by UGC, Govt. of India (Senior Research Fellowship) and MMSB by CSIR, Govt. of India. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
All data generated or analysed during this study are included in this published article. The microarray datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
The study was conceptualized by GVO, experiments were designed by RMN, MMSB and GKV. Acquisition of data were accomplished by RMN and MMSB. Microarray experiments and expression data analysis were done by MMSB, IK, RKR and KP. Interpretation of data was done by RMN, MMSB and GKV. All the authors contributed to the preparation, reading and approval of the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1School of Medical Sciences, University of Hyderabad, Hyderabad 500046, India. 2Ophthalmic Pathology Laboratory, L V Prasad Eye Institute, Hyderabad 500034, India. 3Radiation Signalling and Cancer Biology Section, RB & HSD, BSG, Bhabha Atomic Research Centre, Mumbai 400085, India. 4Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India. 5National Cancer Institute, National Institute of Health (NIH), Bethesda, MD 20892, USA. 6Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.

Received: 6 May 2017 Accepted: 1 November 2017
Published online: 21 November 2017

References
1. Deegan WF. Emerging strategies for the treatment of retinoblastoma. Curr Opin Ophthalmol. 2003;14(5):291–5.
2. DiCicco M, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol. 2000;10(4):255–69.
3. Sachdeva UM, O’Brien JM. Understanding pRb: towards the necessary development of targeted treatments for retinoblastoma. J Clin Invest. 2012;122(2):425–34.
4. Theriault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. Clin Experiment Ophthalmol. 2014;42(1):33–52.
5. Conron TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46(7):617–34.
6. Rushlow DE, Moll BM, Kennett JY, Yee S, Pajovic S, Theriault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Conron TW, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14(4):327–34.
7. Clevens H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313–9.
8. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21(3):283–96.
9. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.
10. Galli R, Binda E, Orfanelli U, Cipollella B, Gitti A, De Viti S, Ficciro R, Foroni C, Dimeo F, Vesco A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011–21.
11. Krishnakanuma S, Mallikarjuna K, Desai N, Muthialu A, Venkatesan N, Sundaram A, Khetan V, Shankunagam GP. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004;88(12):1521–6.
12. Seigel GM, Campbell UM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005;11:729–37.
13. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 2007;13:823–32.
14. Silva AK, Yi H, Hayes SH, Seigel GM, Hackam AS. Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: a potential role for the canonical Wnt signaling pathway. Mol Vis. 2010;16:36–45.
15. Hu H, Deng F, Liu Y, Chen M, Zhang X, Sun X, Dong Z, Liu X, Ge J. Characterization and retinal neuron differentiation of WERB-R1 cancer stem cells. Mol Vis. 2012;18:3388–97.
16. Seigel GM, Chen-Tsi SY, Diaz R, Cassidy L. Comparative analysis of ABCG2+ and ABCG2-retinoblastoma cells in three-dimensional culture. Oncology Lett. 2014;4:1.
17. Zhong X, Li Y, Peng F, Huang B, Lin J, Zhang W, Zheng J, Jiang R, Song G, Ge J. Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int J Cancer. 2007;121(10):2125–31.
18. Balla MM, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R. Phenotypic characterization of retinoblastoma for the presence of putative cancer stem cell markers by flow-cytometry. Invest Ophthalmol Vis Sci. 2009;50(4):1505–14.
19. Lakowiski J, Han YT, Pearson RA, Gonzalez-Cordero A, West EL, Gualdoni S, Barber AC, Hubank M, Ali RR, Sowden JC. Effective transplantation of human embryonic and neuronal stem cell markers by flow cytometry. Invest Ophthalmol Vis Sci. 2009;50(4):1506–15.
20. Barbo RC Jr. The pathology of ocular cancer. Eye (Lond). 2013;27(2):128–38.
21. Duan JJ, Qiu W, Xu SL, Wang B, Ye XZ, Ping YF, Zhang X, Bian XW, Yu SC. Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev. 2013;22(16):2211–39.
22. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3.
23. Kaneshira M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2007;35(Database issue):D344–50.
24. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2012;40(Database issue):D107–12.
25. Dennis G Jr, Sherman BT, Hesp LC, Law M, Fidler I. Cancer stem cells and both CD133+ and CD133− metastatic colon cancer cells develop tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122(4):761–7.
26. Schlag PM. MACC1, a newly identified key regulator of HGF-MET signaling, develops in metastatic cancers. Nat Rev Cancer. 2009;9(1):39–48.
27. Margliotta A, Cinelli E, Fraci D, Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int J Mol Sci. 2017;18(2):476–80.
28. Khan IN, Alarim S, Bora RS, Chaudhary A, Saini KS. Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discov Today. 2015;20(10):1205–16.
29. Gupta R, Vemuganti GK, Reddy VA, Honavar SG. Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med. 2009;133(8):1210–4.
30. Stein U, Walther W, Aft F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schleg PM. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15(1):59–67.
31. Wang G, Fu Z, Li D. MACC1 overexpression and survival in solid tumors: a meta-analysis. Tumour Biol. 2015;36(2):1055–65.